by TractManager | Mar 19, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of alpha-1 antitrypsin (AAT) augmentation therapy with Prolastin or Prolastin-C over other alpha-1 proteinase...
by TractManager | Mar 8, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Vowst (fecal microbiota spores, live-brpk; formerly SER-109) for prevention of recurrent Clostridioides difficile...
by TractManager | Mar 5, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rebyota (fecal microbiota, live-jslm) for prevention of recurrent Clostridioides difficile infection (rCDI).
by TractManager | Mar 5, 2024 | Emerging Technology Report
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) is an investigational oral small molecule sigma-1 receptor agonist for treatment of early Alzheimer disease.
Recent Comments